Guaranteed adherence. Better outcomes.™
Through miniaturized, long-term biopharmaceutical implants, we seek to free patients from medication adherence challenges, minimizing the burden and maximizing the benefit of clinical treatments.
Addressing the biggest challenges in chronic disease treatment – medication non-adherence and tolerability.
An alarming percentage of patients suffering from chronic illnesses don’t take their medications as prescribed, often due to the inconveniences associated with drug administration and/or tolerability, which may be associated with fluctuating drug levels.
Hear from our CEO, Dr. Adam Mendelsohn, on our revolutionary approach to challenges associated with patient behavior.Our long-term solution for life-long conditions.
Our Lead Drug Candidate: NPM-115
GLP-1 for Obesity and Chronic Weight Management
NPM-115 is a miniature, six-month, subdermal, high-dose exenatide drug implant under development for chronic weight management in patients who are obese or overweight. This implant can be conveniently inserted under the skin during a quick outpatient procedure and is designed to provide steady doses of medication for up to six months. Our First-in-Human study, also known as LIBERATE-1 and supportive of NPM-115, is designed to study our exenatide implant in obese and overweight individuals.
Also Developing Candidate: NPM-119
GLP-1 for Type 2 Diabetes
NPM-119 is a miniature, six-month, subdermal, exenatide drug implant under development to treat patients with type 2 diabetes. This device can also be conveniently inserted under the skin during a quick outpatient procedure and is designed to provide steady doses of medication for up to six months.
